{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T07:02:38Z","timestamp":1782802958592,"version":"3.54.5"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T00:00:00Z","timestamp":1727049600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Freiburg"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Daratumumab is an effective therapy in multiple myeloma (MM). We assessed whether daratumumab retreatment may re-induce significant responses and which patients do benefit the most. We hypothesized, that there is effective synergism between daratumumab and alternating antimyeloma drug combinations during retreatment and that retreatment is safe and effective. Here, we analyzed 293 consecutive MM patients receiving daratumumab at our institution from 2016 until 2023 retrospectively, and compared responses, side effects and survival of the first daratumumab treatment line and its retreatment. We identified 22\/293 (8%) patients with daratumumab retreatment. These patients showed an advanced age and ISS\/R-ISS stages, and \u2265\u20093 lines of prior antimyeloma therapy in 91%. Of note, the median durations of the first and subsequent daratumumab treatment were similarly long. We confirmed a therapy break between daratumumab lines as advantageous. Daratumumab retreatment was effective, with responses declining only gradually from its first use to subsequent first and second retreatment with 64%, 46% and 43%, respectively. Interestingly, comparable progression free survival rates were observed with 11.5, 12 months and not reached, respectively. Consistently, adverse events per daratumumab line did not increase. Our findings suggest that well-selected daratumumab-exposed MM patients may show rewarding responses to daratumumab retreatment, the more with alternating antimyeloma combinations, initial good response and CD38-antibody-treatment pauses, thereby proving CD38-antibody-retreatment as feasible, effective and non-toxic. Confirmatory studies are required to further validate our results.<\/jats:p>","DOI":"10.1007\/s00277-024-05991-7","type":"journal-article","created":{"date-parts":[[2024,9,23]],"date-time":"2024-09-23T07:03:04Z","timestamp":1727074984000},"page":"1059-1067","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Response to daratumumab-retreatment in patients with multiple myeloma"],"prefix":"10.1007","volume":"104","author":[{"given":"Laura","family":"Souren","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Ihorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Greil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Engelhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ralph","family":"W\u00e4sch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,9,23]]},"reference":[{"issue":"9983","key":"5991_CR1","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.1016\/S0140-6736(14)60493-1","volume":"385","author":"C R\u00f6llig","year":"2015","unstructured":"R\u00f6llig C, Knop S (2015) Bornh\u00e4user. Multiple myeloma. Lancet 385(9983):2197\u20132208","journal-title":"Lancet"},{"issue":"3","key":"5991_CR2","doi-asserted-by":"publisher","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","volume":"20","author":"S Kumar","year":"2017","unstructured":"Kumar S, Rajkumar V, Kyle R, van Duin M, Sonneveld P, Mateos M-V, Gay F (2017) Anderson. Multiple myeloma. Nat Rev Dis Primers 20(3):17046. https:\/\/doi.org\/10.1038\/nrdp.2017.46","journal-title":"Nat Rev Dis Primers"},{"key":"5991_CR3","unstructured":"Global Cancer Observatory Cancer Today. International Agency for Research on Cancer. https:\/\/gco.iarc.fr\/today"},{"issue":"4","key":"5991_CR4","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/hon.2205","volume":"34","author":"UJM Mey","year":"2016","unstructured":"Mey UJM, Leitner C, Driessen C, Cathomas R, Klingbiel D, Hitz F (2016) Improved survival of older patients with multiple myeloma in the era of Novel agents: Improved Survival in older patients with multiple myeloma. Hematol Oncol 34(4):217\u2013223. https:\/\/doi.org\/10.1002\/hon.2205","journal-title":"Hematol Oncol"},{"issue":"5","key":"5991_CR5","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV (2014) Continued improvement in Survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 28(5):1122\u20131128. https:\/\/doi.org\/10.1038\/leu.2013.313","journal-title":"Leukemia"},{"issue":"2","key":"5991_CR6","doi-asserted-by":"publisher","first-page":"149","DOI":"10.6004\/jnccn.2007.0015","volume":"5","author":"PG Richardson","year":"2007","unstructured":"Richardson PG, Hideshima T, Mitsiades C, Anderson KC (2007) The emerging role of Novel therapies for the treatment of relapsed myeloma. J Natl Compr Canc Netw 5(2):149\u2013162. https:\/\/doi.org\/10.6004\/jnccn.2007.0015","journal-title":"J Natl Compr Canc Netw"},{"key":"5991_CR7","doi-asserted-by":"publisher","first-page":"e504","DOI":"10.14694\/EdBook_AM.2015.35.e504","volume":"35","author":"P Moreau","year":"2015","unstructured":"Moreau P, Touzeau C (2015) Multiple myeloma: from front-line to relapsed therapies. Am Soc Clin Oncol Educational Book No. 35:e504\u2013e511. https:\/\/doi.org\/10.14694\/EdBook_AM.2015.35.e504","journal-title":"Am Soc Clin Oncol Educational Book"},{"issue":"22","key":"5991_CR8","doi-asserted-by":"publisher","first-page":"5443","DOI":"10.1158\/1078-0432.CCR-16-0861","volume":"22","author":"RZ Orlowski","year":"2016","unstructured":"Orlowski RZ, Lonial S (2016) Integration of Novel agents into the care of patients with multiple myeloma. Clin Cancer Res 22(22):5443\u20135452. https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-0861","journal-title":"Clin Cancer Res"},{"issue":"7","key":"5991_CR9","doi-asserted-by":"publisher","first-page":"e451","DOI":"10.1038\/bcj.2016.53","volume":"6","author":"AM Rajan","year":"2016","unstructured":"Rajan AM, Kumar S (2016) New investigational drugs with single-Agent activity in multiple myeloma. Blood Cancer J 6(7):e451\u2013e451. https:\/\/doi.org\/10.1038\/bcj.2016.53","journal-title":"Blood Cancer J"},{"key":"5991_CR10","doi-asserted-by":"crossref","unstructured":"Malavasi F, Funaro A, Roggero S, Horenstein A, Calosso L, Mehta K (1997) Human CD38: a glycoprotein in search of a function. 15(3):95\u201397","DOI":"10.1016\/0167-5699(94)90148-1"},{"issue":"3","key":"5991_CR11","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M De Weers","year":"2011","unstructured":"De Weers M, Tai Y-T, Van Der Veer MS, Bakker JM, Vink T, Jacobs DCH, Oomen LA, Peipp M, Valerius T, Slootstra JW, Mutis T, Bleeker WK, Anderson KC, Lokhorst HM, Van De Winkel JGJ, Parren PW (2011) H. I. Daratumumab, a Novel Therapeutic Human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol 186(3):1840\u20131848. https:\/\/doi.org\/10.4049\/jimmunol.1003032","journal-title":"J Immunol"},{"issue":"3","key":"5991_CR12","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, Syed K, Liu K, Van De Donk NWCJ, Weiss BM, Ahmadi T, Lokhorst HM, Mutis T, Sasser AK (2016) Daratumumab depletes CD38\u2009+\u2009Immune Regulatory cells, promotes T-Cell expansion, and skews T-Cell repertoire in multiple myeloma. Blood 128(3):384\u2013394. https:\/\/doi.org\/10.1182\/blood-2015-12-687749","journal-title":"Blood"},{"key":"5991_CR13","doi-asserted-by":"publisher","unstructured":"Overdijk MB, Verploegen S, B\u00f6gels M, Van Egmond M, Van Bueren JJL, Mutis T, Groen RW, Breij E, Martens AC, Bleeker WK, Parren PW (2015) Antibody-Mediated Phagocytosis Contributes to the Anti-Tumor Activity of the Therapeutic Antibody Daratumumab in Lymphoma and Multiple Myeloma. mAbs 7 (2), 311\u2013320. https:\/\/doi.org\/10.1080\/19420862.2015.1007813","DOI":"10.1080\/19420862.2015.1007813"},{"issue":"3","key":"5991_CR14","doi-asserted-by":"publisher","first-page":"807","DOI":"10.4049\/jimmunol.1501351","volume":"197","author":"MB Overdijk","year":"2016","unstructured":"Overdijk MB, Jansen JHM, Nederend M, Van Lammerts JJ, Groen RWJ, Parren PWHI, Leusen JHW, Boross P (2016) The therapeutic CD38 monoclonal antibody Daratumumab induces programmed cell death via Fc\u03b3 receptor\u2013mediated cross-linking. J Immunol 197(3):807\u2013813. https:\/\/doi.org\/10.4049\/jimmunol.1501351","journal-title":"J Immunol"},{"issue":"6","key":"5991_CR15","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1056\/NEJMoa1714678","volume":"378","author":"M-V Mateos","year":"2018","unstructured":"Mateos M-V, Dimopoulos MA, Cavo M, Suzuki K, Jakubowiak A, Knop S, Doyen C, Lucio P, Nagy Z, Kaplan P, Pour L, Cook M, Grosicki S, Crepaldi A, Liberati AM, Campbell P, Shelekhova T, Yoon S-S, Iosava G, Fujisaki T, Garg M, Chiu C, Wang J, Carson R, Crist W, Deraedt W, Nguyen H, Qi M, San-Miguel J (2018) Daratumumab plus Bortezomib, Melphalan, and Prednisone for untreated myeloma. N Engl J Med 378(6):518\u2013528. https:\/\/doi.org\/10.1056\/NEJMoa1714678","journal-title":"N Engl J Med"},{"issue":"4","key":"5991_CR16","doi-asserted-by":"publisher","first-page":"1066","DOI":"10.1038\/s41375-021-01488-8","volume":"36","author":"T Facon","year":"2022","unstructured":"Facon T, Cook G, Usmani SZ, Hulin C, Kumar S, Plesner T, Touzeau C, Bahlis NJ, Basu S, Nahi H, Goldschmidt H, Quach H, Mohty M, Venner CP, Weisel K, Raje N, Hebraud B, Belhadj-Merzoug K, Benboubker L, Decaux O, Manier S, Caillot D, Ukropec J, Pei H, Van Rampelbergh R, Uhlar CM, Kobos R, Zweegman S (2022) Daratumumab plus Lenalidomide and Dexamethasone in Transplant-Ineligible newly diagnosed multiple myeloma: Frailty Subgroup Analysis of MAIA. Leukemia 36(4):1066\u20131077. https:\/\/doi.org\/10.1038\/s41375-021-01488-8","journal-title":"Leukemia"},{"issue":"8","key":"5991_CR17","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1182\/blood.2020005288","volume":"136","author":"PM Voorhees","year":"2020","unstructured":"Voorhees PM, Kaufman JL, Laubach J, Sborov DW, Reeves B, Rodriguez C, Chari A, Silbermann R, Costa LJ, Anderson LD, Nathwani N, Shah N, Efebera YA, Holstein SA, Costello C, Jakubowiak A, Wildes TM, Orlowski RZ, Shain KH, Cowan AJ, Murphy S, Lutska Y, Pei H, Ukropec J, Vermeulen J, De Boer C, Hoehn D, Lin TS, Richardson PG, Daratumumab (2020) Lenalidomide, Bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN Trial. Blood 136(8):936\u2013945. https:\/\/doi.org\/10.1182\/blood.2020005288","journal-title":"Blood"},{"issue":"1","key":"5991_CR18","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/leu.2011.310","volume":"26","author":"B Mohty","year":"2012","unstructured":"Mohty B, El-Cheikh J, Yakoub-Agha I, Avet-Loiseau H, Moreau P, Mohty M (2012) Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018Retreatment\u2019 approaches in the era of Novel agents. Leukemia 26(1):73\u201385. https:\/\/doi.org\/10.1038\/leu.2011.310","journal-title":"Leukemia"},{"issue":"1","key":"5991_CR19","doi-asserted-by":"publisher","first-page":"e104","DOI":"10.1002\/hsr2.104","volume":"2","author":"C Hulin","year":"2019","unstructured":"Hulin C, De La Rubia J, Dimopoulos MA, Terpos E, Katodritou E, Hungria V, De Samblanx H, Stoppa A-M, Aagesen J, Sargin D, Sioni A, Belch A, Diels J, Olie RA, Robinson D, Potamianou A, Van De Velde H, Delforge M (2019) Bortezomib Retreatment for Relapsed and Refractory multiple myeloma in real-world clinical practice. Health Sci Rep 2(1):e104. https:\/\/doi.org\/10.1002\/hsr2.104","journal-title":"Health Sci Rep"},{"issue":"5","key":"5991_CR20","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","volume":"11","author":"J Mikhael","year":"2021","unstructured":"Mikhael J, Belhadj-Merzoug K, Hulin C, Vincent L, Moreau P, Gasparetto C, Pour L, Spicka I, Vij R, Zonder J, Atanackovic D, Gabrail N, Martin TG, Perrot A, Bensfia S, Weng Q, Brillac C, Semiond D, Mac\u00e9 S, Corzo KP, Leleu X (2021) A phase 2 study of Isatuximab Monotherapy in patients with multiple Myeloma who are refractory to Daratumumab. Blood Cancer J 11(5):89. https:\/\/doi.org\/10.1038\/s41408-021-00478-4","journal-title":"Blood Cancer J"},{"issue":"6","key":"5991_CR21","doi-asserted-by":"publisher","first-page":"626","DOI":"10.1111\/ejh.13942","volume":"110","author":"A Abdallah","year":"2023","unstructured":"Abdallah A, Mahmoudjafari Z, Ahmed N, Cui W, Shune L, McGuirk J, Mohan M, Rehman Mohyuddin G, Afrough A, Alkharabsheh O, Atrash S (2023) Clinical efficacy of Retreatment of Daratumumab-based therapy (D2) in Daratumumab-Refractory multiple myeloma. Eur J Haematol 110(6):626\u2013632. https:\/\/doi.org\/10.1111\/ejh.13942","journal-title":"Eur J Haematol"},{"issue":"9","key":"5991_CR22","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.3324\/haematol.2016.148189","volume":"101","author":"M Engelhardt","year":"2016","unstructured":"Engelhardt M, Dold SM, Ihorst G, Zober A, Moller M, Reinhardt H, Hieke S, Schumacher M, Wasch R (2016) Geriatric Assessment in multiple myeloma patients: validation of the International Myeloma Working Group (IMWG) score and comparison with other Common Comorbidity scores. Haematologica 101(9):1110\u20131119. https:\/\/doi.org\/10.3324\/haematol.2016.148189","journal-title":"Haematologica"},{"issue":"5","key":"5991_CR23","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3324\/haematol.2016.162693","volume":"102","author":"M Engelhardt","year":"2017","unstructured":"Engelhardt M, Domm A-S, Dold SM, Ihorst G, Reinhardt H, Zober A, Hieke S, Baayen C, M\u00fcller SJ, Einsele H, Sonneveld P, Landgren O, Schumacher M, W\u00e4sch RA (2017) Concise revised Myeloma Comorbidity Index as a valid prognostic instrument in a large cohort of 801 multiple myeloma patients. Haematologica 102(5):910\u2013921. https:\/\/doi.org\/10.3324\/haematol.2016.162693","journal-title":"Haematologica"},{"issue":"17","key":"5991_CR24","doi-asserted-by":"publisher","first-page":"2991","DOI":"10.1002\/cncr.32178","volume":"125","author":"AK Nooka","year":"2019","unstructured":"Nooka AK, Joseph NS, Kaufman JL, Heffner LT, Gupta VA, Gleason C, Boise LH, Lonial S (2019) Clinical efficacy of Daratumumab, Pomalidomide, and Dexamethasone in patients with relapsed or refractory myeloma: utility of re-treatment with Daratumumab among refractory patients. Cancer 125(17):2991\u20133000. https:\/\/doi.org\/10.1002\/cncr.32178","journal-title":"Cancer"},{"issue":"1","key":"5991_CR25","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/leu.2016.186","volume":"31","author":"P Moreau","year":"2017","unstructured":"Moreau P, Joshua D, Chng W-J, Palumbo A, Goldschmidt H, H\u00e1jek R, Facon T, Ludwig H, Pour L, Niesvizky R, Oriol A, Rosi\u00f1ol L, Suvorov A, Gaidano G, Pika T, Weisel K, Goranova-Marinova V, Gillenwater HH, Mohamed N, Aggarwal S, Feng S, Dimopoulos MA (2017) Impact of prior treatment on patients with relapsed multiple myeloma treated with Carfilzomib and Dexamethasone vs Bortezomib and Dexamethasone in the phase 3 ENDEAVOR Study. Leukemia 31(1):115\u2013122. https:\/\/doi.org\/10.1038\/leu.2016.186","journal-title":"Leukemia"},{"issue":"8","key":"5991_CR26","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.clml.2019.09.623","volume":"20","author":"M-V Mateos","year":"2020","unstructured":"Mateos M-V, Sonneveld P, Hungria V, Nooka AK, Estell JA, Barreto W, Corradini P, Min C-K, Medvedova E, Weisel K, Chiu C, Schecter JM, Amin H, Qin X, Ukropec J, Kobos R, Spencer A, Daratumumab (2020) Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in patients with previously treated multiple myeloma: three-year follow-up of CASTOR. Clin Lymphoma Myeloma Leuk 20(8):509\u2013518. https:\/\/doi.org\/10.1016\/j.clml.2019.09.623","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"9","key":"5991_CR27","doi-asserted-by":"publisher","first-page":"e699","DOI":"10.1016\/j.clml.2021.04.012","volume":"21","author":"J Lu","year":"2021","unstructured":"Lu J, Fu W, Li W, Hu J, An G, Wang Y, Fu C, Chen L, Jin J, Cen X, Ge Z, Cai Z, Niu T, Qi M, Sun S, Gai X, Liu W, Liu W, Yang X, Huang X, Daratumumab (2021) Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: phase 3 LEPUS (MMY3009) study. Clin Lymphoma Myeloma Leuk 21(9):e699\u2013e709. https:\/\/doi.org\/10.1016\/j.clml.2021.04.012","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"14","key":"5991_CR28","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, Rabin N, Orlowski RZ, Komarnicki M, Suzuki K, Plesner T, Yoon S-S, Ben Yehuda D, Richardson PG, Goldschmidt H, Reece D, Lisby S, Khokhar NZ, O\u2019Rourke L, Chiu C, Qin X, Guckert M, Ahmadi T, Moreau P (2016) Daratumumab, Lenalidomide, and Dexamethasone for multiple myeloma. N Engl J Med 375(14):1319\u20131331. https:\/\/doi.org\/10.1056\/NEJMoa1607751","journal-title":"N Engl J Med"},{"issue":"8","key":"5991_CR29","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, Spicka I, Hungria V, Munder M, Mateos MV, Mark TM, Qi M, Schecter J, Amin H, Qin X, Deraedt W, Ahmadi T, Spencer A, Sonneveld P (2016) Daratumumab, Bortezomib, and Dexamethasone for multiple myeloma. N Engl J Med 375(8):754\u2013766. https:\/\/doi.org\/10.1056\/NEJMoa1606038","journal-title":"N Engl J Med"},{"issue":"7","key":"5991_CR30","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","volume":"128","author":"IS Nijhof","year":"2016","unstructured":"Nijhof IS, Casneuf T, Van Velzen J, Van Kessel B, Axel AE, Syed K, Groen RWJ, Van Duin M, Sonneveld P, Minnema MC, Zweegman S, Chiu C, Bloem AC, Mutis T, Lokhorst HM, Van De Sasser AK (2016) Donk, N. W. C. J. CD38 expression and complement inhibitors affect response and resistance to Daratumumab Therapy in Myeloma. Blood 128(7):959\u2013970. https:\/\/doi.org\/10.1182\/blood-2016-03-703439","journal-title":"Blood"},{"issue":"21","key":"5991_CR31","doi-asserted-by":"publisher","first-page":"6430","DOI":"10.1182\/bloodadvances.2023010162","volume":"7","author":"O De Perez","year":"2023","unstructured":"De Perez O, Reiman L, Jayabalan DS, Walker ZJ, Bosma G, Keller AL, Parzych SE, Abbott D, Idler BM, Ribadeneyra D, Niesvizky R, Forsberg PA, Mark TM, Sherbenou DW (2023) CD38 antibody re-treatment in Daratumumab-Refractory multiple myeloma after time on other therapies. Blood Adv 7(21):6430\u20136440. https:\/\/doi.org\/10.1182\/bloodadvances.2023010162","journal-title":"Blood Adv"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05991-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-024-05991-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-024-05991-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T21:45:15Z","timestamp":1743889515000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-024-05991-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,23]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["5991"],"URL":"https:\/\/doi.org\/10.1007\/s00277-024-05991-7","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,23]]},"assertion":[{"value":"7 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is registered at Freiburg Register of Clinical Trials under protocol FRKS004511 and was approved by the Ethics Committee of the University of Freiburg (EV 23-1110_1-S1). It was performed according to the guidelines of the Declaration of Helsinki and Good Clinical Practice.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All patients gave their written informed consent for institutionally initiated research studies in accordance with the institutional review board guidelines.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"RW consulted for Amgen, BMS\/Celgene, Janssen, Novartis, Kite\/Gilead, Pfizer, Sanofi and Takeda, he received research funding from Janssen and Sanofi, and travel support from Janssen, Kite\/Gilead, Pfizer and BMS. The other authors declare no competing financial interest related to this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}